Patterns of CTCF and ZFHX3 mutation and associated outcomes in endometrial cancer

Journal of the National Cancer Institute

Volumn 107, Issue 11, 2015, Pages

  Walker, Christopher J ^a,c   Miranda, Mario A ^a,c   O'Hern, Matthew J ^a,c   McElroy, Joseph P ^b,c   Coombes, Kevin R ^b,c   Bundschuh, Ralf ^d   Cohn, David E ^a,c   Mutch, David G ^e   Goodfellow, Paul J ^a,c  

^a Division of Gynecologic Oncology   (United States)

^b Biochemistry and Molecular Biology College of Medicine 985950 Nebraska Medical Center   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR CTCF; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ZFHX3 PROTEIN; CCCTC-BINDING FACTOR; HOMEODOMAIN PROTEIN; REPRESSOR PROTEIN; ZFHX3 PROTEIN, HUMAN;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; COPY NUMBER VARIATION; ENDOMETRIUM CANCER; FEMALE; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GERMLINE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MUTATION RATE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE; ADULT; AGED; BAYES THEOREM; DISEASE FREE SURVIVAL; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; RISK; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; BAYES THEOREM; CARCINOMA, ENDOMETRIOID; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE DELETION; HOMEODOMAIN PROTEINS; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; REPRESSOR PROTEINS;

EID: 84946887794     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv249     Document Type: Article

References (57)

1. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642-646.
2. Hamilton CA, Kapp DS, Chan JK. Clinical aspects of uterine papillary serous carcinoma. Curr Opin Obstet Gynecol. 2008;20(1):26-33.
3. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
4. Berg A, Hoivik EA, Mjos S, et al. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. Oncotarget. 2015;6(2):1327-1339.
5. Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73.
6. Fukuchi T, Sakamoto M, Tsuda H, et al. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res. 1998;58(16):3526-3528.
7. Kohler MF, Berkholz A, Risinger JI, et al. Mutational analysis of the estrogenreceptor gene in endometrial carcinoma. Obstet Gynecol. 1995;86(1):33-37.
8. Koul A, Willen R, Bendahl PO, et al. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer. 2002;94(9):2369-2379.
9. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997;57(18):3935-3940.
10. Xiao T, Wallace J, Felsenfeld G. Specific sites in the C terminus of CTCF interact with the SA2 subunit of the cohesin complex and are required for cohesin-dependent insulation activity. Mol Cell Biol. 2011;31(11):2174-2183.
11. Rubio ED, Reiss DJ, Welcsh PL, et al. CTCF physically links cohesin to chromatin. Proc Natl Acad Sci U S A. 2008;105(24):8309-8314.
12. Parelho V, Hadjur S, Spivakov M, et al. Cohesins functionally associate with CTCF on mammalian chromosome arms. Cell. 2008;132(3):422-433.
13. Stedman W, Kang H, Lin S, et al. Cohesins localize with CTCF at the KSHV latency control region and at cellular c-myc and H19/Igf2 insulators. EMBO J. 2008;27(4):654-666.
14. Wendt KS, Yoshida K, Itoh T, et al. Cohesin mediates transcriptional insulation by CCCTC-binding factor. Nature. 2008;451(7180):796-801.
15. Weinstein JN, Collisson EA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45(10):1113-1120.
16. Kemp CJ, Moore JM, Moser R, et al. CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer. Cell Rep. 2014;7(4):1020-1029.
17. Zighelboim I, Mutch DG, Knapp A, et al. High frequency strand slippage mutations in CTCF in MSI-positive endometrial cancers. Hum Mutat. 2014;35(1):63-65.
18. Kondo K, Chilcote RR, Maurer HS, et al. Chromosome abnormalities in tumor cells from patients with sporadic Wilms' tumor. Cancer Res. 1984;44(11):5376-5381.
19. Maw MA, Grundy PE, Millow LJ, et al. A third Wilms' tumor locus on chromosome 16q. Cancer Res. 1992;52(11):3094-3098.
20. Devilee P, van Vliet M, van Sloun P, et al. Allelotype of human breast carcinoma: a second major site for loss of heterozygosity is on chromosome 6q. Oncogene. 1991;6(9):1705-1711.
21. Hansen LL, Jensen LL, Dimitrakakis C, et al. Allelic imbalance in selected chromosomal regions in ovarian cancer. Cancer Genet Cytogenet. 2002;139(1):1-8.
22. Kataoka H, Miura Y, Joh T, et al. Alpha-fetoprotein producing gastric cancer lacks transcription factor ATBF1. Oncogene. 2001;20(7):869-873.
23. Piao Z, Park C, Kim JJ, et al. Deletion mapping of chromosome 16q in hepatocellular carcinoma. Br J Cancer. 1999;80(5-6):850-854.
24. Snijders AM, Nowee ME, Fridlyand J, et al. Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in fallopian tube carcinoma. Oncogene. 2003;22(27):4281-4286.
25. Sun X, Frierson HF, Chen C, et al. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet. 2005;37(4):407-412.
26. Sun X, Zhou Y, Otto KB, et al. Infrequent mutation of ATBF1 in human breast cancer. J Cancer Res Clin Oncol. 2007;133(2):103-105.
27. Rakha EA, Green AR, Powe DG, et al. Chromosome 16 tumor-suppressor genes in breast cancer. Genes Chromosomes Cancer. 2006;45(6):527-535.
28. Kaspar P, Dvorakova M, Kralova J, et al. Myb-interacting protein, ATBF1, represses transcriptional activity of Myb oncoprotein. J Biol Chem. 1999;274(20):14422-14428.
29. Miura Y, Kataoka H, Joh T, et al. Susceptibility to killer T cells of gastric cancer cells enhanced by Mitomycin-C involves induction of ATBF1 and activation of p21 (Waf1/Cip1) promoter. Microbiol Immunol. 2004;48(2):137-145.
30. Morinaga T, Yasuda H, Hashimoto T, et al. A human alpha-fetoprotein enhancer-binding protein, ATBF1, contains four homeodomains and seventeen zinc fingers. Mol Cell Biol. 1991;11(12):6041-6049.
31. Nojiri S, Joh T, Miura Y, et al. ATBF1 enhances the suppression of STAT3 signaling by interaction with PIAS3. Biochem Biophys Res Commun. 2004;314(1):97-103.
32. Yasuda H, Mizuno A, Tamaoki T, et al. ATBF1, a multiple-homeodomain zinc finger protein, selectively down-regulates AT-rich elements of the human alpha-fetoprotein gene. Mol Cell Biol. 1994;14(2):1395-1401.
33. Dong XY, Sun X, Guo P, et al. ATBF1 inhibits estrogen receptor (ER) function by selectively competing with AIB1 for binding to the ER in ER-positive breast cancer cells. J Biol Chem. 2010;285(43):32801-32809.
34. Dong XY, Guo P, Sun X, et al. Estrogen up-regulates ATBF1 transcription but causes its protein degradation in estrogen receptor-alpha-positive breast cancer cells. J Biol Chem. 2011;286(16):13879-13890.
35. Sun X, Fu X, Li J, et al. Heterozygous deletion of Atbf1 by the Cre-loxP system in mice causes preweaning mortality. Genesis. 2012;50(11):819-827.
36. Sun X, Fu X, Li J, et al. Deletion of atbf1/zfhx3 in mouse prostate causes neoplastic lesions, likely by attenuation of membrane and secretory proteins and multiple signaling pathways. Neoplasia. 2014;16(5):377-389.
37. Zighelboim I, Goodfellow PJ, Gao F, et al. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol. 2007;25(15):2042-2048.
38. Billingsley CC, Cohn DE, Mutch DG, et al. Polymerase varepsilon (POLE) mutations in endometrial cancer: Clinical outcomes and implications for Lynch syndrome testing. Cancer. 2015;121(3):386-394.
39. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491-498.
40. Forbes SA, Bhamra G, Bamford S, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet. 2008;Chapter 10:Unit 10 11.
41. Bacher JW, Flanagan LA, Smalley RL, et al. Development of a fluorescent multiplex assay for detection of MSI-High tumors. Dis Markers. 2004;20(4-5):237-250.
42. Kupets R, Le T, Le T, et al. The role of adjuvant therapy in endometrial cancer. J Obstet Gynaecol Can. 2013;35(4):375-379.
43. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1-452.
44. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105(2):103-104.
45. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Ser B Stat Methodol. 1995;57(1):289-300.
46. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10-17.
47. Boeva V, Popova T, Lienard M, et al. Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data. Bioinformatics. 2014;30(24):3443-3450.
48. Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3):568-576.
49. Kim TM, Laird PW, Park PJ. The landscape of microsatellite instability in colorectal and endometrial cancer genomes. Cell. 2013;155(4):858-868.
50. Novetsky AP, Zighelboim I, Thompson DM Jr, et al. Frequent mutations in the RPL22 gene and its clinical and functional implications. Gynecol Oncol. 2013;128(3):470-474.
51. Tritz D, Pieretti M, Turner S, et al. Loss of heterozygosity in usual and special variant carcinomas of the endometrium. Hum Pathol. 1997;28(5):607-612.
52. Pere H, Tapper J, Wahlstrom T, et al. Distinct chromosomal imbalances in uterine serous and endometrioid carcinomas. Cancer Res. 1998;58(5):892-895.
53. Le Gallo M, Bell DW. The emerging genomic landscape of endometrial cancer. Clin Chem. 2014;60(1):98-110.
54. Gonzalez-Perez A, Lopez-Bigas N. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am J Hum Genet. 2011;88(4):440-449.
55. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68(4):820-823.
56. Davoli T, Xu AW, Mengwasser KE, et al. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell. 2013;155(4):948-962.
57. Solimini NL, Xu Q, Mermel CH, et al. Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science. 2012;337(6090):104-109.